LILLY'S LYMPHOMA DRUG MOVES TO PHASE III TRIAL

Eli Lilly has launched a Phase III trial of enzastaurin in patients with non-Hodgkin's lymphoma.

In the trial, which is known as Preventing Relapse in Lymphoma Using Daily Enzastaurin, or PRELUDE, 459 patients with diffuse large B-cell lymphoma who have achieved remission following first-line therapy will be given either enzastaurin or placebo for up to three years.

The primary endpoint is disease-free survival, and investigators also will be looking for biomarkers that could help correlate patient response to clinical trial outcome.